News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
March 28, 2024
Pharmaceutical Technology
Read Now
Press Release
CRISPR drug licensing deals secure $21bn in top three therapy areas over five years
March 28, 2024
Pharmaceutical Technology
Read Now
News
Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 6, 2024
Read Now
Press Release
Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference
March 6, 2024
Read Now
News
Benjamin Oakes and the Promise of CRISPR
March 5, 2024
Sounds of Science
Read Now
Press Release
Benjamin Oakes and the Promise of CRISPR
March 5, 2024
Sounds of Science
Read Now
News
The Age of CRISPR: Engineering the Future of Genetic Medicine
February 23, 2024
TEDxBerkeley
Read Now
Press Release
The Age of CRISPR: Engineering the Future of Genetic Medicine
February 23, 2024
TEDxBerkeley
Read Now